Telomir's stock jumped nearly 39% in after-hours trading following news that its lead compound, Telomir-1, showed potential in reversing cancer-related DNA changes in aggressive prostate cancer models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback